Tobin Schilke, a newly appointed director at Lexeo Therapeutics, Inc., filed an initial statement of beneficial ownership on November 17, 2026, disclosing no securities held as of the November 14, 2026 event date.

Key Highlights

  • Reporting person: Schilke Tobin, identified as a Director of Lexeo Therapeutics, Inc.
  • Event date: The date of the event requiring the statement is listed as November 14, 2026.
  • No securities held: The filing explicitly states, "No securities are beneficially owned."
  • No non-derivative holdings: Table I, covering non-derivative securities, contains no entries.
  • No derivative holdings: Table II, covering derivative securities such as options or warrants, also contains no entries.
  • Signed by attorney-in-fact: The form was signed by Youjin Choi as attorney-in-fact on November 17, 2026.

Lexeo Therapeutics Director Schilke Tobin Reports No Initial Beneficial Ownership

According to the filing, Schilke Tobin submitted a Form 3 initial statement of beneficial ownership with the U.S. Securities and Exchange Commission on November 17, 2026, in connection with becoming a director of Lexeo Therapeutics, Inc. (NASDAQ:LXEO). The event requiring the statement is dated November 14, 2026. The filing was submitted by one reporting person and was not an amendment to a prior filing.

The filing discloses no holdings of any kind. Table I, which covers non-derivative securities beneficially owned, contains no reported positions. Table II, which covers derivative securities such as puts, calls, warrants, options, and convertible securities, likewise contains no entries. The form includes the explicit notation: "No securities are beneficially owned." The issuer address on record is 345 Park Avenue South, Floor 6, New York, New York 10010.

The form was executed by Youjin Choi, identified as attorney-in-fact, and filed on November 17, 2026. Schilke Tobin is listed solely in the capacity of Director, with no officer title or other relationship indicated.

What Was Disclosed

Lexeo Therapeutics director Schilke Tobin filed an initial beneficial ownership statement covering the November 14, 2026 event date, reporting no direct or indirect holdings in either non-derivative or derivative securities of the company.